Cancer Therapy-Induced Right Ventricular Systolic and Diastolic Dysfunction Assessed Using Conventional Echocardiographic Indices: A Prospective Observational Study

Background/Objectives: Cancer treatment can impair right ventricular (RV) systolic and diastolic function by altering cardiomyocyte metabolism and inducing cell death. The incidence and prognosis of cancer therapy-induced RV involvement remain uncertain. We assessed RV diastolic changes and their association with systolic RV and LV dysfunction in cancer patients. Methods: We prospectively observed 60 adults (91.7% female, aged 31 to 74 years) with breast or gastrointestinal cancer receiving chemotherapy for a median of 381 days (IQR 187, 464), excluding those with cardiovascular or pulmonary disease. RV diastolic function was assessed using the 2010 right heart echocardiographic guidelines. RV systolic dysfunction was defined by abnormal values in at least two of the following RV indices: fractional area change (RVFAC), systolic tissue Doppler velocity (RVS’), tricuspid annular plane systolic excursion, or myocardial performance index. LV dysfunction was defined by abnormal LV ejection fraction or average systolic LV tissue Doppler velocity. Results: RV systolic dysfunction was found in 7 patients (11.7%), RV diastolic dysfunction in 12 (30.7%), and LV dysfunction in 11 (18.3%). Generalised estimating equations showed early decreases in RVS’ and RVFAC at the first month (β = −0.68, p = 0.016; β = −2.2, p = 0.006), and later changes in RV early diastolic tissue velocity (RVe′) and the ratio of early RV filling velocity (RVE) to RVe′ (RVE/e′) at the third month (β = −1.03, p = 0.005; β = 0.35, p = 0.034). Higher RVFAC values were linked to lower odds of LV dysfunction (OR 0.88, p = 0.002). RVe′ was associated with RV systolic dysfunction (OR 0.61, p < 0.001), with a threshold of 10 cm/s (AUC 0.81; 95% CI: 0.69, 0.93). Conclusions: Conventional echocardiographic parameters may facilitate the detection of RV systolic and diastolic dysfunction during cancer therapy. Early alterations and the prognostic value of RV parameters support the necessity for their routine monitoring.

Authors

Institutions

Publication Details

Journal
Diagnostics
Published
2026-11-13
DOI
https://doi.org/10.3390/diagnostics16223764
Primary Topic
Chemotherapy-induced cardiotoxicity and mitigation
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Cancer Therapy-Induced Right Ventricular Systolic and Diastolic Dysfunction Assessed Using Conventional Echocardiographic Indices: A Prospective Observational Study

Svetoslava Elefterova Slavcheva, Nikolay Vladimirov Conev, Атанас Ангелов
3 links
Diagnostics
Chemotherapy-induced cardiotoxicity and mitigation
article

Cancer Therapy-Induced Right Ventricular Systolic and Diastolic Dysfunction Assessed Using Conventional Echocardiographic Indices: A Prospective Observational Study

Svetoslava Elefterova Slavcheva, Nikolay Vladimirov Conev, Атанас Ангелов
article en

Abstract

Background/Objectives: Cancer treatment can impair right ventricular (RV) systolic and diastolic function by altering cardiomyocyte metabolism and inducing cell death. The incidence and prognosis of cancer therapy-induced RV involvement remain uncertain. We assessed RV diastolic changes and their association with systolic RV and LV dysfunction in cancer patients. Methods: We prospectively observed 60 adults (91.7% female, aged 31 to 74 years) with breast or gastrointestinal cancer receiving chemotherapy for a median of 381 days (IQR 187, 464), excluding those with cardiovascular or pulmonary disease. RV diastolic function was assessed using the 2010 right heart echocardiographic guidelines. RV systolic dysfunction was defined by abnormal values in at least two of the following RV indices: fractional area change (RVFAC), systolic tissue Doppler velocity (RVS’), tricuspid annular plane systolic excursion, or myocardial performance index. LV dysfunction was defined by abnormal LV ejection fraction or average systolic LV tissue Doppler velocity. Results: RV systolic dysfunction was found in 7 patients (11.7%), RV diastolic dysfunction in 12 (30.7%), and LV dysfunction in 11 (18.3%). Generalised estimating equations showed early decreases in RVS’ and RVFAC at the first month (β = −0.68, p = 0.016; β = −2.2, p = 0.006), and later changes in RV early diastolic tissue velocity (RVe′) and the ratio of early RV filling velocity (RVE) to RVe′ (RVE/e′) at the third month (β = −1.03, p = 0.005; β = 0.35, p = 0.034). Higher RVFAC values were linked to lower odds of LV dysfunction (OR 0.88, p = 0.002). RVe′ was associated with RV systolic dysfunction (OR 0.61, p < 0.001), with a threshold of 10 cm/s (AUC 0.81; 95% CI: 0.69, 0.93). Conclusions: Conventional echocardiographic parameters may facilitate the detection of RV systolic and diastolic dysfunction during cancer therapy. Early alterations and the prognostic value of RV parameters support the necessity for their routine monitoring.

DiagnosticsVol. 16(22)
Medical University of Varna (BG), University Hospital St. Marina (BG)
Good health and well-being
Chemotherapy-induced cardiotoxicity and mitigation
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon